Prelude Therapeutics partners with Lilly to test PRT13722 combos with Verzenio, imlunestrant in Phase 1 breast cancer trial
Prelude Therapeutics entered a clinical trial collaboration and supply agreement with Lilly for abemaciclib and imlunestrant. Deal supports a Phase 1 study of PRT13722 combinations with abemaciclib or imlunestrant in HR+/HER2- breast cancer. Trial is cleared under an FDA IND, with enrollment expected to start in Q4 202